Single User License
INR 102255
Site License
INR 204510
Corporate User License
INR 306765

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chugai Pharmaceutical Co., Ltd.-Product Pipeline Review-2015

Chugai Pharmaceutical Co., Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Chugai Pharmaceutical Co., Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Chugai Pharmaceutical Co., Ltd.-Product Pipeline Review-2015', provides an overview of the Chugai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chugai Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Chugai Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Chugai Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Chugai Pharmaceutical Co., Ltd.'s pipeline products

Reasons To Buy

Evaluate Chugai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Chugai Pharmaceutical Co., Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Chugai Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Chugai Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chugai Pharmaceutical Co., Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Chugai Pharmaceutical Co., Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Chugai Pharmaceutical Co., Ltd. Snapshot 7

Chugai Pharmaceutical Co., Ltd. Overview 7

Key Information 7

Key Facts 7

Chugai Pharmaceutical Co., Ltd.-Research and Development Overview 8

Key Therapeutic Areas 8

Chugai Pharmaceutical Co., Ltd.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Chugai Pharmaceutical Co., Ltd.-Pipeline Products Glance 17

Chugai Pharmaceutical Co., Ltd.-Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

Chugai Pharmaceutical Co., Ltd.-Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

Chugai Pharmaceutical Co., Ltd.-Early Stage Pipeline Products 21

Preclinical Products/Combination Treatment Modalities 21

Discovery Products/Combination Treatment Modalities 22

Chugai Pharmaceutical Co., Ltd.-Drug Profiles 23

ibandronate sodium 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

atezolizumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

gantenerumab 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

lebrikizumab 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

obinutuzumab 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

pertuzumab 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

SA-237 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

tocilizumab 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

trastuzumab emtansine 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

basimglurant 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

bevacizumab 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

codrituzumab 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

nemolizumab 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

pictilisib 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

polatuzumab vedotin 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

RG-1577 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

RG-1662 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

RG-7304 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

taselisib 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Antibody for Colorectal Cancer 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

CH-5036249 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

CH-5164840 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

CH-5449302 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

CH-5451098 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

cVE-199 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

maxacalcitol 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Monoclonal Antibody for Hepatitis C 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

NA-255 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

PCO-371 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Chugai Pharmaceutical Co., Ltd.-Pipeline Analysis 74

Chugai Pharmaceutical Co., Ltd.-Pipeline Products by Target 74

Chugai Pharmaceutical Co., Ltd.-Pipeline Products by Route of Administration 77

Chugai Pharmaceutical Co., Ltd.-Pipeline Products by Molecule Type 78

Chugai Pharmaceutical Co., Ltd.-Pipeline Products by Mechanism of Action 79

Chugai Pharmaceutical Co., Ltd.-Recent Pipeline Updates 81

Chugai Pharmaceutical Co., Ltd.-Dormant Projects 106

Chugai Pharmaceutical Co., Ltd.-Discontinued Pipeline Products 107

Discontinued Pipeline Product Profiles 107

nitazoxanide 107

bevacizumab 107

onartuzumab 108

orlistat 108

PA-799 108

parsatuzumab 108

RG-7167 109

tocilizumab 109

Chugai Pharmaceutical Co., Ltd.-Company Statement 110

Chugai Pharmaceutical Co., Ltd.-Locations And Subsidiaries 111

Head Office 111

Other Locations & Subsidiaries 111

Chugai Pharmaceutical Co., Ltd.-Key Manufacturing Facilities 114

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116

List of Tables

Chugai Pharmaceutical Co., Ltd., Key Information 7

Chugai Pharmaceutical Co., Ltd., Key Facts 7

Chugai Pharmaceutical Co., Ltd.-Pipeline by Indication, 2015 9

Chugai Pharmaceutical Co., Ltd.-Pipeline by Stage of Development, 2015 11

Chugai Pharmaceutical Co., Ltd.-Monotherapy Products in Pipeline, 2015 12

Chugai Pharmaceutical Co., Ltd.-Partnered Products in Pipeline, 2015 13

Chugai Pharmaceutical Co., Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 14

Chugai Pharmaceutical Co., Ltd.-Out-Licensed Products in Pipeline, 2015 15

Chugai Pharmaceutical Co., Ltd.-Out-Licensed Products/ Combination Treatment Modalities, 2015 16

Chugai Pharmaceutical Co., Ltd.-Pre-Registration, 2015 17

Chugai Pharmaceutical Co., Ltd.-Phase III, 2015 18

Chugai Pharmaceutical Co., Ltd.-Phase II, 2015 19

Chugai Pharmaceutical Co., Ltd.-Phase I, 2015 20

Chugai Pharmaceutical Co., Ltd.-Preclinical, 2015 21

Chugai Pharmaceutical Co., Ltd.-Discovery, 2015 22

Chugai Pharmaceutical Co., Ltd.-Pipeline by Target, 2015 75

Chugai Pharmaceutical Co., Ltd.-Pipeline by Route of Administration, 2015 77

Chugai Pharmaceutical Co., Ltd.-Pipeline by Molecule Type, 2015 78

Chugai Pharmaceutical Co., Ltd.-Pipeline Products by Mechanism of Action, 2015 79

Chugai Pharmaceutical Co., Ltd.-Recent Pipeline Updates, 2015 81

Chugai Pharmaceutical Co., Ltd.-Dormant Developmental Projects,2015 106

Chugai Pharmaceutical Co., Ltd.-Discontinued Pipeline Products, 2015 107

Chugai Pharmaceutical Co., Ltd., Other Locations 111

Chugai Pharmaceutical Co., Ltd., Subsidiaries 112

Chugai Pharmaceutical Co., Ltd., Key Manufacturing Facilities 114

List of Figures

Chugai Pharmaceutical Co., Ltd.-Pipeline by Top 10 Indication, 2015 9

Chugai Pharmaceutical Co., Ltd.-Pipeline by Stage of Development, 2015 11

Chugai Pharmaceutical Co., Ltd.-Monotherapy Products in Pipeline, 2015 12

Chugai Pharmaceutical Co., Ltd.-Partnered Products in Pipeline, 2015 13

Chugai Pharmaceutical Co., Ltd.-Pipeline by Top 10 Target, 2015 74

Chugai Pharmaceutical Co., Ltd.-Pipeline by Top 10 Route of Administration, 2015 77

Chugai Pharmaceutical Co., Ltd.-Pipeline by Top 10 Molecule Type, 2015 78

Chugai Pharmaceutical Co., Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Chugai Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd. - Key Therapeutics; Chugai Pharmaceutical Co., Ltd. - Pipeline Overview and Promising Molecules; Chugai Pharmaceutical Co., Ltd. - News; Chugai Pharmaceutical Co., Ltd. - Latest Updates; Chugai Pharmaceutical Co., Ltd. - Pipeline; Chugai Pharmaceutical Co., Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com